Introduction
============

Colorectal cancer (CRC) is one of the most common malignant tumors worldwide, and its incidence has significantly increased during the past 20 years ([@b1-or-44-02-0449],[@b2-or-44-02-0449]). While surgical treatments have significantly increased the 5-year survival rate of patients with most types of primary tumors, late-stage CRC patients still have a 5-year overall survival rate of \<10% ([@b3-or-44-02-0449]). Radiotherapy and chemotherapy can be used for patients with different stages of CRC, but are not recommended for patients with functional organs and for extended treatment of \>6 months ([@b4-or-44-02-0449]). Recently, molecular-targeting agents have emerged as promising treatments for prolonging the overall survival of CRC patients, ([@b5-or-44-02-0449]). This has created an urgent need to identify new targets that can be used for the early diagnosis and personalized treatment of CRC.

Testis-specific protein Y-encoded-like 5 (*TSPYL5*), located on chromosome 8q22.1, is a member of the *TSPY-L* gene family ([@b6-or-44-02-0449]), and is also a member of the nucleosome assembly protein (NAP) superfamily ([@b7-or-44-02-0449]). TSPYL5 has been shown to interact with ubiquitin-specific protease to reduce the tumor-suppressor activity of p53 ([@b8-or-44-02-0449]). Accumulating evidence suggests a critical role for TSPYL5 in tumor progression. For example, TSPYL5 was shown to modulate the growth of A549 cells and their sensitization to the detrimental effects of toxic agents via regulation of p21(WAF1/Cip1) and the PTEN/AKT pathway ([@b9-or-44-02-0449]). Restoration of *TSPYL5* by a DNA methyltransferase inhibitor was demonstrated to suppress the growth of gastric cancer cells ([@b10-or-44-02-0449]). Furthermore, *TSPYL5* functions as a tumor suppressor in ovarian cancer ([@b11-or-44-02-0449]) and an oncogene in breast cancer ([@b12-or-44-02-0449]).

Endoplasmic reticulum (ER) is made up of membranous tubules and vesicles. An accumulation of unfolded and misfolded proteins usually leads to ER stress (ERS) ([@b13-or-44-02-0449],[@b14-or-44-02-0449]). ERS is mediated by pancreatic endoplasmic reticulum kinase (PERK), inositol-requiring enzyme 1 (IRE1), and activating transcription factor 6 (ATF6) for the purpose of maintaining protein homeostasis ([@b15-or-44-02-0449]). As a major signal-transducing event, ERS can induce apoptosis to enhance the cytotoxicity of various chemotherapeutic drugs ([@b16-or-44-02-0449],[@b17-or-44-02-0449]). It is now well-established that targeting the ERS response is an effective strategy for suppressing the growth of human hepatocellular carcinoma ([@b18-or-44-02-0449]), breast cancer ([@b19-or-44-02-0449]), and ovarian cancer cells ([@b20-or-44-02-0449]). Although some investigators have focused on the role of ERS in CRC, few studies have examined the mechanism by which TSPYL5 affects ERS and CRC progression.

In the present study, we investigated the expression patterns and clinical significance of TSPYL5 in CRC patients via a GEPIA database analysis and an analysis of clinical samples. Furthermore, we explored the biological function of TSPYL5 and its effects on ERS-associated factors for the purpose of identifying molecular pathways involved in the malignant behaviors of CRC cells.

Materials and methods
=====================

### GEPIA database analysis

The levels of *TSPYL5* expressed in CRC tumors and normal tissues were identified using the online Gene Expression Profiling Interactive Analysis (GEPIA) database (<http://gepia.cancer-pku.cn/index.html>), which is an interactive website that includes information for 9,736 tumor samples and 8,587 normal tissue samples obtained from TCGA and GTEx projects. The GEPIA database was also used to generate survival curves based on the levels of *TSPYL5* gene expression in CRC tissues, as determined by the log-rank test.

### Clinical tissues

Thirty pairs of CRC and para-carcinoma tissue samples were collected from CRC patients who underwent surgical resection of their tumors at the Renmin Hospital of Wuhan University from February 2017 to December 2018 (age range, 45--86 years; Females, 41%). None of the patients had received any radiotherapy or chemotherapy prior to surgery, and each patient provided a written informed consent. All the tissue samples were immediately frozen in liquid nitrogen and stored at −80°C until use. The protocol for this study was approved by the Ethics Committee of The Renmin Hospital of Wuhan University (Wuhan, Hubei, China). All procedures involving human subjects were performed in accordance with the 1964 Helsinki declaration.

### Quantitative real time PCR

Total RNA was isolated from frozen tissues using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) and reversed transcribed into cDNA with an iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Inc.). Quantitative real-time PCR was performed using iTaq Universal SYBR Green Supermix (Bio-Rad Laboratories, Inc.) on an ABI 7500 Fast Real-Time PCR System (Applied Biosystems). The PCR reaction conditions consisted of 95°C for 3 min, followed by 40 cycles of 95°C for 30 sec and 60°C for 30 sec. The primer sequences used were as follows: *TSPYL5* forward, GGTTGTTTTTTGTGTAGTTGTAGT and reverse, CATCACAAACATACAACTATACCA. *TSPYL5* expression was normalized to that of GAPDH, and analyzed using the 2^−ΔΔCq^ method ([@b21-or-44-02-0449]).

### Cell culture and transfection

Human CRC cell lines HCT116 and HT29 were obtained from the American Type Culture Collection (ATCC) and cultured in Dulbecco\'s modified Eagle\'s medium (DMEM; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific, Inc.). Both cell lines were maintained in a humidified atmosphere containing 5% CO~2~ at 37°C.

For TSPYL5 overexpression, the cDNA for TSPYL5 without its 3′-UTR was inserted into a pcDNA3.1 vector using Lipofectamine 2000 transfection reagent (both from Invitrogen; Thermo Fisher Scientific, Inc.) to generate the recombinant vector, pcDNA3.1-TSPYL5. Subsequently, HCT116 and HT29 cells were seeded into 6-well plates and transfected with pcDNA3.1-TSPYL5 or empty pcDNA3.1, to produce TSPYL5 and negative control (NC) groups, respectively. Non-transfected cells served as a blank group.

### EdU proliferation assay

A Cell Light™ EDU Apollo^®^488 In Vitro Imaging Kit (Guangzhou RiboBio) was used to detect the proliferation rates of the transfected CRC cells, according to instructions provided by the manufacturer. Briefly, HCT116 and HT29 cells were fixed with 4% paraformaldehyde for 15 min, washed three times with PBS, and then stained with 200 µl of 1X Apollo solution for 30 min. After another wash with PBS, the cells with EdU-positive signals were detected by flow cytometry (BD Biosciences).

### Flow cytometry

Cell apoptosis was detected with an Annexin V-fluorescein Isothiocyanate Propidium Iodide (FITC/PI) apoptosis detection kit (cat. no. 70-AP101-100; Hangzhou MultiSciences Biotech Co., Ltd.). Briefly, HCT116 and HT29 cells were harvested, washed twice in PBS, and then stained with Annexin V-FIFC/PI for 15 min; after which, they were analyzed by flow cytometry (BD Biosciences). The total apoptotic rate, including early apoptosis and late apoptosis, was calculated and averaged for three experiments.

### Hoechst 33342 staining

HCT116 and HT29 cells in their logarithmic growth phase were plated into 6-well plates and incubated for 48 h. The cells were then washed twice with PBS, incubated in the dark for 10 min with Hoechst 33342 nucleic acid stain (Sigma-Aldrich; Merck KGaA), and subsequently examined for their nuclear morphology under a fluorescence microscope (Olympus Corp.).

### Transwell assay

Cell migration and invasion abilities were examined using Transwell assays. Briefly, \~2×10^4^ HCT116 or HT29 cells suspended in 1 ml of serum-free medium were added into the upper chamber (without Matrigel for migration or with Matrigel for invasion) of a Transwell plate (Costar, cat. no. 3422; Corning Life Sciences). The lower chamber was filled with 500 µl of culture medium containing 10% FBS. After a 48-h incubation, the migrated cells in the lower chamber were fixed with formaldehyde for 5 min, and then stained with 0.5% crystal violet solution (Sigma-Aldrich; Merck KGaA). The stained cells were observed under a phase-contrast microscope (Olympus Corp.) at a magnification of ×200, and various visual fields were randomly selected for cell counting.

### Transmission electron microscopy

ERS was examined by transmission electron microscopy as previously described ([@b22-or-44-02-0449]). In brief, transfected HCT116 and HT29 cells were harvested, fixed in glutaraldehyde, and then dehydrated in serial dilutions of acetone (30, 80 and 90%). Next, ultrathin sections were produced by embedding cells in Ultracut (Leica, Germany) and cutting into 60-nm sections. After staining with uranyl acetate, the ultrathin sections were examined with a JEM-1230 transmission electron microscope (JEOL Ltd.).

### Western blot analysis

Total cellular protein was obtained by lysing CRC cells in RIPA buffer (Pierce; Thermo Fisher Scientific, Inc.) that contained a protease inhibitor cocktail and phosphatase inhibitors (Sigma-Aldrich; Merck KGaA). Protein concentrations were detected using a BCA Protein Assay Kit (Thermo Fisher Scientific, Inc.). Samples containing \~30 µg of protein were separated by 10% SDS-PAGE, and the protein bands were transferred onto PVDF membranes (Invitrogen; Thermo Fisher Scientific, Inc.). The membranes were then blocked with 5% skim milk and subsequently incubated overnight with primary antibodies against TSPYL5 (cat. no. ab203657, dilution: 1:800; Abcam), caspase-1 (cat. no. ab62698, dilution: 1:800; Abcam), caspase-3 (cat. no. ab49822, dilution: 1:500; Abcam), Bax (cat. no. M00183-2, dilution: 1:1,000, Boster), ATF4 (cat. no. A00371, dilution: 1:500; Boster), CHOP (cat. no. A00311, dilution: 1:500; Boster), and GAPDH (cat. no. ab9485, dilution: 1:800; Abcam) at 4°C. On the following day, the membranes were incubated with an HRP conjugated secondary antibody (cat. no. ab97080, dilution: 1:30,000; Abcam). The immunostained proteins were detected using an enhanced chemiluminescence kit (Thermo Fisher Scientific, Inc.). Quantification of western blot bands was performed using Image-Pro Plus (Version 6; Media Cybernetics, Inc.).

### Statistical analysis

All statistical analyses were performed using IBM SPSS Statistics for Windows, version 21.0 (IBM Corp.). Quantitative results are expressed as the mean ± SD of data obtained from at least three experiments. Differences between two groups were analyzed using Student\'s t-test and differences among groups were assessed by one-way analysis of variance (ANOVA). A P-value \<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Expression of TSPYL5 was downregulated in CRC tissues

To determine differences in *TSPYL5* expression in CRC tumor tissues vs. normal tissues, the *TSPYL5* mRNA levels in COAD (colon adenocarcinoma) and READ (rectum adenocarcinoma) were analyzed using the GEPIA database. As shown in [Fig. 1A](#f1-or-44-02-0449){ref-type="fig"}, *TSPYL5* expression was significantly lower in the COAD and READ tissues when compared to levels in the respective adjacent normal tissues (P\<0.05). To verify the expression results obtained from the GEPIA database, we determined the levels of *TSPYL5* expression in 30 pairs of CRC tumor and para-carcinoma tissues by quantitative real-time PCR. As shown in [Fig. 1B](#f1-or-44-02-0449){ref-type="fig"}, *TSPYL5* expression was significantly downregulated in the tumor tissues when compared with that noted in the para-carcinoma tissues (P\<0.05). Western blot analyses of 8 pairs of representative tissues showed a result similar to that obtained by quantitative real-time PCR ([Fig. 1C and D](#f1-or-44-02-0449){ref-type="fig"}, P\<0.01). These results suggest the role of TSPYL5 as a possible tumor suppressor in CRC.

### Overexpression of TSPYL5 suppresses the proliferation and promotes the apoptosis of CRC cells

To further confirm that TSPYL5 acts as a tumor suppressor in CRC *in vitro*, two CRC cell lines, HCT116 and HT29, were transfected with pcDNA3.1-TSPYL5, and then used in a series of functional experiments. Firstly, RT-qPCR and western blot analysis were performed to validated the overexpression of TSPYL5 in HCT116 and HT29 cell lines. Results showed that expression of TSPYL5 was enhanced after cell transfection ([Fig. 2A and B](#f2-or-44-02-0449){ref-type="fig"}).

As shown in [Fig. 3A](#f3-or-44-02-0449){ref-type="fig"}, flow cytometry of EdU-positive cells revealed that TSPYL5 overexpression decreased the percentage of EDU-positive HCT116 cells from 46.7 to 31.5% and the percentage of EDU-positive HT29 cells from 33.5 to 27.6%. In addition, flow cytometry with Annexin V/PI double staining was performed to evaluate cell apoptosis. As illustrated in [Fig. 3B](#f3-or-44-02-0449){ref-type="fig"}, the apoptotic rate of the TSPYL5-overexpressing HCT116 cells was significantly increased (27.69±0.52%) when compared to the apoptotic rates of cells in the blank (6.81±0.30%) and NC (7.05±0.49%) groups (P\<0.001). Similarly, overexpression of TSPYL5 promoted the apoptosis of HT29 cells ([Fig. 3B](#f3-or-44-02-0449){ref-type="fig"}, P\<0.001). Next, HCT116 and HT29 cells stained with a DNA-specific dye (Hoechst 33342) were examined for morphologic changes. The results showed that TSPYL5-overexpressing HCT116 and HT29 cells exhibited bright fluorescence and characteristic features of apoptosis, including chromatin condensation when compared with cells in the NC and blank groups ([Fig. 3C](#f3-or-44-02-0449){ref-type="fig"}).

Overexpression of TSPYL5 suppresses the migration and invasion abilities of CRC cells. Transwell assays were performed to investigate the effect of TSPYL5 on the migration and invasion abilities of CRC cells. As shown in [Fig. 4A](#f4-or-44-02-0449){ref-type="fig"}, overexpression of TSPYL5 significantly reduced the numbers of migrated HCT116 cells when compared to the numbers of migrated control cells (TSPYL5-overexpressing HCT116 cells vs. NC cells: 77.00±12.12 vs. 128.00±4.36; P\<0.05), and similar results were obtained for the TSPYL5-overexpressing HT29 cells (TSPYL5-overexpressing HT29 cells vs. NC cells: 70.33±12.66 vs. 126.33±10.26, P\<0.05). Moreover, after transfection with pcDNA3.1-TSPYL5, the numbers of invading HCT166 and HT29 ([Fig. 4B](#f4-or-44-02-0449){ref-type="fig"}) cells were also decreased when compared to the numbers of invading NC cells (TSPYL5-overexpressing HCT116 cells vs. NC cells: 49.33±3.06 vs. 88.00±12.12, P\<0.05 and TSPYL5-overexpressing HT29 cells vs. NC cells: 32.00±7.94 vs. 67.33±15.57, P\<0.05).

### Effects of TSPYL5 overexpression on ERS and associated proteins

As the effect of TSPYL5 on ERS in CRC cells remains unknown, we next investigated whether TSPYL5 overexpression could induce ERS. First, ERS was detected using a transmission electron microscope. As shown in [Fig. 5](#f5-or-44-02-0449){ref-type="fig"}, larger amounts of swollen ER were observed in the cytoplasm of HCT116 and HT29 cells that overexpressed TSPYL5, and that change was not observed in the control or NC cells. Next, western blot analyses were performed to examine the direct effects of TSPYL5 on ERS and apoptosis. As shown in [Fig. 6](#f6-or-44-02-0449){ref-type="fig"}, the levels of caspase-1, caspase-3, bcl-2-like protein 4 (Bax), activating transcription factor 4 (ATF4) and CCAAT-enhancer-binding protein homologous protein (CHOP) proteins were upregulated after TSPYL5 overexpression. These observed changes indicated that TSPYL5 overexpression-induced apoptosis may be correlated with activated ERS in CRC cells.

Discussion
==========

Several studies have reported that *TSPYL5* acts as a tumor-suppressor gene in gastric ([@b10-or-44-02-0449]) and ovarian cancer ([@b11-or-44-02-0449]), yet its clinical significance and biological role in CRC remain unclear. In the present study, we first found that TSPYL5 expression was significantly lower in CRC tissues when compared with that noted in adjacent normal tissues. The methylation levels of *TSPYL5* were found to be significantly increased in HCC tissues when compared with those levels in adjacent non-tumor tissues, and that may be an independent unfavorable factor affecting disease-free survival ([@b6-or-44-02-0449]). Aberrant methylation of the *TSPYL5* promoter has been reported to be associated with high-risk oral leukoplakia ([@b23-or-44-02-0449]). In addition, *TSPYL5* gene expression has been correlated with the survival of patients with all grades of endometrial cancer ([@b24-or-44-02-0449]).

Next, we further demonstrated that overexpression of TSPYL5 significantly suppressed cell proliferation, migration and invasion, and induced apoptosis in two human CRC cell lines. Our findings were consistent with those reported by Shao *et al* ([@b11-or-44-02-0449]), who observed that ovarian cancer inhibition ability could be elevated by miR-629 inhibitor-mediated upregulation of TSPYL5. Lakshmanan *et al* ([@b25-or-44-02-0449]) showed that MUC16 regulates TSPYL5 via the JAK2/STAT3/GR signaling axis in regards to lung cancer cell growth and metastasis. Kumar *et al* ([@b26-or-44-02-0449]) revealed that TSPYL5 overexpression in prostate cancer cells increased the sensitivity of those cells to chemotherapy drugs. Strikingly, a recent study by Huang and Luo ([@b27-or-44-02-0449]) demonstrated that overexpression of TSPYL5 promoted apoptosis in HT29 cells and reduced cell proliferation, migration and invasion, which further validates our results ([@b27-or-44-02-0449]).

Recently, interest has developed in determining how to utilize the endoplasmic reticulum stress (ERS) response as a method for treating cancer. In the present study, larger amounts of swollen ER were observed in the cytoplasm of HCT116 and HT29 cells that exhibited overexpression of TSPYL5, indicating an increase in ERS. We also found that TSPYL5 overexpression triggered ERS that significantly increased the levels of ATF4, CHOP, caspase-1, caspase-3, and Bax proteins in CRC cells. These findings suggest that ER stress can trigger apoptosis via ER stress-specific cell-death signals, including CHOP and caspase, as previously described ([@b28-or-44-02-0449]). ERS-induced apoptosis in CRC was previously described in another report ([@b29-or-44-02-0449],[@b30-or-44-02-0449]). Shikonin was found to induce apoptotic cell death by activating ERS, accompanied by increases in Bax and CHOP protein levels ([@b30-or-44-02-0449]). Moreover, interleukin-1 receptor associated kinase 2 (*IRAK2*), as a potential tumor suppressor to counterbalance oncogenic Smad ubiquitylation regulatory factor 1 (Smurf1) in response to ERS, also induced cell death ([@b31-or-44-02-0449]). To the best of our knowledge, the effects of TSPYL5 on ERS activation have not been previously investigated. Our present findings suggest that TSPYL5 overexpression suppresses cell proliferation, migration, and invasion via activation of ERS. While knockdown experiments of TSPYL5 must also be performed in further *in vitro* and *in vivo* investigations.

Overall, the data presented here demonstrated that TSPYL5 exerted anticancer effects on HCT116 and HT29 cells by activating ERS-induced apoptosis, as evidenced by an accumulation of caspase-1, caspase-3, and Bax proteins, induction of ERS markers, and induction of ATF4 and CHOP. These findings indicate that targeting the ERS response using TSPYL5 may be a promising strategy for treating CRC. This approach should be investigated in future clinical trials.
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![Expression of TSPYL5 was downregulated in CRC tissues. (A) TSPYL5 expression levels in COAD (colon adenocarcinoma) T, tumor \[n=275\], N, normal \[n=349\] and READ (rectum adenocarcinoma) T \[n=92\], N \[n=318\] were investigated via the GEPIA database. (B) The levels of *TSPYL5* mRNA expression in 30 paired tumor tissues and para-carcinoma tissues were investigated by quantitative real-time PCR analysis. (C) The levels of TSPYL5 protein expression in 8 paired tumor tissues (T1-T8) and para-carcinoma tissues (P1-P8) were investigated by western blotting. (D) Quantitative analysis of TSPYL5 protein levels in 8 paired tumor tissues and para-carcinoma tissues. \*P\<0.05, \*\*P\<0.01. P, para-carcinoma tissues; T, CRC tumor tissues. CRC, colorectal cancer; TSPYL5, testis-specific protein Y-encoded-like 5; GEPIA, Gene Expression Profiling Interactive Analysis. T, Tumor tissues; N, non-tumor tissues; n, number of samples used.](OR-44-02-0449-g00){#f1-or-44-02-0449}

![Validation of expression of TSPYL5 in CRC HCT116 and HT29 cells lines after transfection with the overexpression vector. (A) RT-qPCR was used to measure the mRNA expression of *TSPYL5*. (B) Western blot analysis was used to detect the expression of TSPYL5 protein. \*\*\*P\<0.001, compared to the negative control (NC) group. CRC, colorectal cancer; TSPYL5, testis-specific protein Y-encoded-like 5.](OR-44-02-0449-g01){#f2-or-44-02-0449}

![Effects of TSPYL5 overexpression on the proliferation and apoptosis of CRC cells. HCT116 and HT29 cells were transfected with pcDNA3.1-TSPYL5 or empty pcDNA3.1, and subsequently divided into TSPYL5 and negative control (NC) groups, respectively. (A) EdU flow cytometry was used to analyze the percentage of EdU-positive cells. (B) Flow cytometric analysis of cell apoptosis rates using Annexin V-FITC/PI double labeling. Data represent the mean ± SD of results from three individual experiments; \*\*\*P\<0.001 vs. NC. (C) Fluorescence assay of Hoechst 33342 staining. HCT116 and HT29 cells were stained with Hoechst 33342 staining solution and visualized under a fluorescence microscope. CRC, colorectal cancer; TSPYL5, testis-specific protein Y-encoded-like 5.](OR-44-02-0449-g02){#f3-or-44-02-0449}

![Effects of TSPYL5 overexpression on the migration and invasion abilities of CRC cells. HCT116 and HT29 cells were transfected with pcDNA3.1-TSPYL5 or empty pcDNA3.1, and subsequently divided into TSPYL5 and negative control (NC) groups, respectively. Transwell assays were performed to investigate cell migration (A) and invasion (B) Representative images were captured after transfection for 48 h (left panel). A quantification of migrated or invasive cells is shown in the right panel. Data represent the mean ± SD of results from three individual experiments; \*P\<0.05 vs. the NC group. CRC, colorectal cancer; TSPYL5, testis-specific protein Y-encoded-like 5.](OR-44-02-0449-g03){#f4-or-44-02-0449}

![TSPYL5 overexpression induces endoplasmic reticulum stress (ERS) in CRC cells. HCT116 and HT29 cells were transfected with pcDNA3.1-TSPYL5 or empty pcDNA3.1, and subsequently divided into TSPYL5 and negative control (NC) groups, respectively. Photomicrographs of HCT and HT29 cells collected by transmission electron microscopy (magnification ×12,000; red arrow, endoplasmic reticulum). CRC, colorectal cancer; TSPYL5, testis-specific protein Y-encoded-like 5.](OR-44-02-0449-g04){#f5-or-44-02-0449}

![Effects of TSPYL5 overexpression on ERS and its associated proteins. HCT116 and HT29 cells were transfected with pcDNA3.1-TSPYL5 or empty pcDNA3.1, and subsequently divided into TSPYL5 and negative control (NC) groups, respectively. (A) Western blot analysis of the protein levels of caspase-1, caspase-3, bcl-2-like protein 4 (Bax), activating transcription factor 4 (ATF4) and CCAAT-enhancer-binding protein homologous protein (CHOP) in the HT29 and HCT116 cells in the TSPYL5 overexpression and NC groups. (B) Quantification of the levels of caspase-1, caspase-3, Bax, ATF4, and CHOP protein expression as determined by western blot analysis. \*P\<0.05, \*\*P\<0.01 and \*\*\*P\<0.001 vs. the NC group. CRC, colorectal cancer; TSPYL5, testis-specific protein Y-encoded-like 5.](OR-44-02-0449-g05){#f6-or-44-02-0449}
